Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Decreases By 19.7%

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the recipient of a significant drop in short interest in March. As of March 15th, there was short interest totalling 1,670,000 shares, a drop of 19.7% from the February 28th total of 2,080,000 shares. Based on an average trading volume of 526,700 shares, the days-to-cover ratio is presently 3.2 days. Currently, 14.1% of the company’s stock are short sold.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of JSPR. Boxer Capital Management LLC acquired a new stake in shares of Jasper Therapeutics during the fourth quarter worth $7,483,000. Integral Health Asset Management LLC lifted its stake in shares of Jasper Therapeutics by 85.7% in the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $13,897,000 after acquiring an additional 300,000 shares during the period. Braidwell LP boosted its holdings in shares of Jasper Therapeutics by 47.9% in the fourth quarter. Braidwell LP now owns 714,658 shares of the company’s stock valued at $15,279,000 after acquiring an additional 231,358 shares in the last quarter. Soleus Capital Management L.P. boosted its holdings in shares of Jasper Therapeutics by 11.2% in the fourth quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company’s stock valued at $31,951,000 after acquiring an additional 150,755 shares in the last quarter. Finally, Stempoint Capital LP acquired a new position in shares of Jasper Therapeutics during the fourth quarter worth about $2,892,000. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. JMP Securities reissued a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a research report on Monday, January 6th. UBS Group started coverage on Jasper Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $38.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Jasper Therapeutics in a report on Tuesday, March 11th. Royal Bank of Canada decreased their target price on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research note on Thursday, January 9th. Finally, BMO Capital Markets started coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective on the stock. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $62.50.

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock opened at $4.46 on Monday. The stock has a market capitalization of $67.00 million, a price-to-earnings ratio of -0.94 and a beta of 2.23. The firm’s fifty day simple moving average is $5.69 and its 200-day simple moving average is $14.72. Jasper Therapeutics has a 12 month low of $4.38 and a 12 month high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last announced its earnings results on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.35). Analysts anticipate that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.